Back to Results
First PageMeta Content
Medicine / Human respiratory syncytial virus / Astellas Pharma / Virosome / Health / Vaccination / Biology / Vaccine


Microsoft Word - 140106_RSV Vaccine_ClearPath_Mymetics_Eg_FIN.docx
Add to Reading List

Document Date: 2014-01-06 01:14:18

Open Document

File Size: 170,85 KB

Share Result on Facebook

City

Epalinges / Rockville / Tokyo / /

Company

RRD International / ClearPath Development Company / Astellas Pharma Inc. / RSV Corporation / Mymetics Corporation / Wyeth / Mymetics Christophe Lamps USA / /

Country

Switzerland / Japan / United States / /

Currency

USD / /

/

Event

M&A / Business Partnership / /

Facility

Mymetics pipeline / /

IndustryTerm

vaccine product / biotechnology / external cutting edge science / pharmaceutical / virosome vaccine technology / biopharmaceutical / pharmaceuticals / finance capabilities / manufacturing / /

MedicalCondition

HIV / infections / influenza / malaria / Kidney diseases / cardiovascular disease / infectious diseases / infection / /

Organization

Michelle Linn Office / /

Person

Michelle Linn / Chuck Finn / Kenji Yasukawa / Ronald Kempers / Toon Stegmann / George Siber / /

/

Position

global category leader / Executive Vice President and Chief Scientific Officer / Vice President and Chief Strategy Officer / CEO / Chairman / Forward / Private / /

ProvinceOrState

Maryland / /

Technology

Neuroscience / biotechnology / virosome vaccine technology / Transplantation / /

URL

www.mymetics.com / www.clearpathdevco.com / www.astellas.com/en / /

SocialTag